Are Genetic Therapies for Epilepsy Ready for the Clinic?

Overview

Journal Epilepsy Curr

Publisher Sage Publications

Date 2023 Sep 4

PMID 37662470

Authors

James S Street

Yichen Qiu

Gabriele Lignani

Affiliations

Soon will be listed here.

Abstract

In recent years, there has been a significant increase in preclinical studies to test genetic therapies for epilepsy. Some of these therapies have advanced to clinical trials and are being tested in patients with monogenetic or focal refractory epilepsy. This article provides an overview of the current state of preclinical studies that show potential for clinical translation. Specifically, we focus on genetic therapies that have demonstrated a clear effect on seizures in animal models and have the potential to be translated to clinical settings. Both therapies targeting the cause of the disease and those that treat symptoms are discussed. We believe that the next few years will be crucial in determining the potential of genetic therapies for treating patients with epilepsy.

Citing Articles

Genetic Testing in Epilepsy: Improving Outcomes and Informing Gaps in Research.

Habela C, Schatz K, Kelley S Epilepsy Curr. 2024; :15357597241232881.

PMID: 39554273 PMC: 11562134. DOI: 10.1177/15357597241232881.

Recent advances and current status of gene therapy for epilepsy.

Cai A, Gao K, Zhang F, Jiang Y World J Pediatr. 2024; 20(11):1115-1137.

PMID: 39395088 DOI: 10.1007/s12519-024-00843-w.

Flavonoids as therapeutic agents for epilepsy: unveiling anti-inflammatory and antioxidant pathways for novel treatments.

Zhang Y, Hu X, Zou L Front Pharmacol. 2024; 15:1457284.

PMID: 39329119 PMC: 11424894. DOI: 10.3389/fphar.2024.1457284.

NORSE/FIRES: how can we advance our understanding of this devastating condition?.

Champsas D, Zhang X, Rosch R, Ioannidou E, Gilmour K, Cooray G Front Neurol. 2024; 15:1426051.

PMID: 39175762 PMC: 11338801. DOI: 10.3389/fneur.2024.1426051.

Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management.

Anand A, Shrivastava A, Singh K, Barik R, Gayakwad D, S J CNS Neurol Disord Drug Targets. 2024; 24(1):60-73.

PMID: 39069797 DOI: 10.2174/0118715273332140240724093837.

References

Ahonen S, Nitschke S, Grossman T, Kordasiewicz H, Wang P, Zhao X . Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. Brain. 2021; 144(10):2985-2993. PMC: 8634080. DOI: 10.1093/brain/awab194. View

Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, Dubouch C . Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013; 8:176. PMC: 4225757. DOI: 10.1186/1750-1172-8-176. View

Wykes R, Heeroma J, Mantoan L, Zheng K, MacDonald D, Deisseroth K . Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med. 2012; 4(161):161ra152. PMC: 3605784. DOI: 10.1126/scitranslmed.3004190. View

Colasante G, Qiu Y, Massimino L, Di Berardino C, Cornford J, Snowball A . In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain. 2020; 143(3):891-905. PMC: 7089667. DOI: 10.1093/brain/awaa045. View

Burbano L, Li M, Jancovski N, Jafar-Nejad P, Richards K, Sedo A . Antisense oligonucleotide therapy for KCNT1 encephalopathy. JCI Insight. 2022; 7(23). PMC: 9746904. DOI: 10.1172/jci.insight.146090. View

Agostinho A, Mietzsch M, Zangrandi L, Kmiec I, Mutti A, Kraus L . Dynorphin-based "release on demand" gene therapy for drug-resistant temporal lobe epilepsy. EMBO Mol Med. 2019; 11(10):e9963. PMC: 6783645. DOI: 10.15252/emmm.201809963. View

Mazarati A, Hohmann J, Bacon A, Liu H, Sankar R, Steiner R . Modulation of hippocampal excitability and seizures by galanin. J Neurosci. 2000; 20(16):6276-81. PMC: 6772610. View

Paz J, Davidson T, Frechette E, Delord B, Parada I, Peng K . Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat Neurosci. 2012; 16(1):64-70. PMC: 3700812. DOI: 10.1038/nn.3269. View

Lenk G, Jafar-Nejad P, Hill S, Huffman L, Smolen C, Wagnon J . Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome. Ann Neurol. 2020; 87(3):339-346. PMC: 7064908. DOI: 10.1002/ana.25676. View

10.

Thijs R, Surges R, OBrien T, Sander J . Epilepsy in adults. Lancet. 2019; 393(10172):689-701. DOI: 10.1016/S0140-6736(18)32596-0. View

11.

Walker M, Kullmann D . Optogenetic and chemogenetic therapies for epilepsy. Neuropharmacology. 2019; 168:107751. DOI: 10.1016/j.neuropharm.2019.107751. View

12.

Noe F, Pool A, Nissinen J, Gobbi M, Bland R, Rizzi M . Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008; 131(Pt 6):1506-15. DOI: 10.1093/brain/awn079. View

13.

Katzel D, Nicholson E, Schorge S, Walker M, Kullmann D . Chemical-genetic attenuation of focal neocortical seizures. Nat Commun. 2014; 5:3847. PMC: 4050272. DOI: 10.1038/ncomms4847. View

14.

Li M, Jancovski N, Jafar-Nejad P, Burbano L, Rollo B, Richards K . Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model. J Clin Invest. 2021; 131(23). PMC: 8631599. DOI: 10.1172/JCI152079. View

15.

Haberman R, Samulski R, McCown T . Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med. 2003; 9(8):1076-80. DOI: 10.1038/nm901. View

16.

Wykes R, Lignani G . Gene therapy and editing: Novel potential treatments for neuronal channelopathies. Neuropharmacology. 2017; 132:108-117. DOI: 10.1016/j.neuropharm.2017.05.029. View

17.

Snowball A, Chabrol E, Wykes R, Shekh-Ahmad T, Cornford J, Lieb A . Epilepsy Gene Therapy Using an Engineered Potassium Channel. J Neurosci. 2019; 39(16):3159-3169. PMC: 6468110. DOI: 10.1523/JNEUROSCI.1143-18.2019. View

18.

Melin E, Nanobashvili A, Avdic U, Gotzsche C, Andersson M, Woldbye D . Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy. Mol Ther Methods Clin Dev. 2019; 15:179-193. PMC: 6807261. DOI: 10.1016/j.omtm.2019.09.004. View

19.

Valassina N, Brusco S, Salamone A, Serra L, Luoni M, Giannelli S . Scn1a gene reactivation after symptom onset rescues pathological phenotypes in a mouse model of Dravet syndrome. Nat Commun. 2022; 13(1):161. PMC: 8748984. DOI: 10.1038/s41467-021-27837-w. View

20.

Hristova K, Martinez-Gonzalez C, Watson T, Codadu N, Hashemi K, Kind P . Medial septal GABAergic neurons reduce seizure duration upon optogenetic closed-loop stimulation. Brain. 2021; 144(5):1576-1589. PMC: 8219369. DOI: 10.1093/brain/awab042. View